Scientific Program 8th Edition

Download the page_white_acrobat SYMPOSIUM PROGRAM

THURSDAY, 9th June 2011

THURSDAY, 9th June 2011
8.00 – 8.45 REGISTRATION
8.45 – 9.15 WELCOMING
9.15 – 10.15 OPENING SPECIAL LECTURE.
9.15 – 9.40 Genetics in our daily clinical practice
William McKenna (London, UK)
9.45 – 10.10 Personalised Cardiovascular Medicine. Is genetics the answer?
Valentin Fuster (New York, USA)
10.15 – 12.00
WHAT’S NEW IN STEM CELL THERAPY FOR CARDIAC REPAIR? – I
10.15 – 10.30 The association between progenitor cells and cardiovascular integrity. What’s new?
Amir Lerman (Rochester, USA)
10.30 – 10.45 Original versus Modified cells. What’s new?
André Terzic (Roechester, USA)
10.45- 11.00 Mechanisms of benefit of cells for cardiac repair. What’s new?
Stefanie Dimmeler (Frankfurt, Germany)
11.00 – 11.15 Myocardial tissue engineering. What’s new?
Karen Christman (San Diego, USA)
11.15 – 11.30 Cells on the shelf. Are allogenic the answer?
Dominique Charron (Paris, France)
11.30 – 12.00 Panel Discussion
12.00 – 12.30 Coffee Break
12.30 – 13.45 WHAT’S NEW IN STEM CELL THERAPY FOR CARDIAC REPAIR? – II
12.30 – 12.45 Stem cell therapy for STEMI. The new Pan European proposal.
Anthony Marthur (London, UK) 
12.45 – 13.00 Clinical trials. What’s new?
Stefan Janssens (Leuven, Belgium) 
13.00 – 13.15 Lessons from other organs. What’s new?
Lilach Lerman (Rochester, USA)
13.15 – 13.30 Cardiovascular translational research in stem cell therapy. The vision of scientific organizations
Nabil Dib (San Diego, USA)
13.30 – 13.50 Panel Discussion
13.50 – 15.00 Lunch and Poster Exhibition
In this “Poster Exhibition” research teams involved in the topic of the Symposium will have the opportunity of presenting selected parts of their work to the audience.

A Poster Review Committee will select which the best posters of the session are. At the end of the session, the verdict will be communicated. The winners of the Posters Awards will have to present their work oral presentation the following day in the morning, in the session named “Best Posters Presentation”, when they will receive their prize.

For more information regarding the Poster Exhibition and Poster Awards, please contact us via e-mail at posters@cardiovascularcelltherapy.com.

15.00 – 16.30 LATE BREAKING CLINICAL TRIALS IN STEM CELL THERAPY – I
15.00 – 15.15 BMMNCs in acute myocardial infarction: update on TIME and LateTIME and the future of the Cardiovascular Cell Therapy Research Network
Robert Simari (Rochester, USA)
15.15 – 15.30 Repair AMI. 5 year and counting
Andreas Zeiher (Frankfurt, Germany)
15.30 – 15.45 Selected CD133+ endothelial progenitor cells to create angiogenesis in patients with refractory angina. Preliminary safety results of the PROGENITOR randomized trial
Pilar Jimenez-Quevedo (Madrid, Spain)
15.45 – 16.00 Safety and early efficacy findings of SDF-1 for the treatment of chronic heart failure
Mark S. Penn (Cleveland, USA)
16.00 – 16.30 Panel Discussion
16.30 – 18.15
SPECIAL THEMED SESSION: PULMONARY HYPERTENSION. INNOVATION FOR AN OLD DRAMA
16.30 – 16.45 Pulmonary Hypertension in perspective. Dimensions, concepts, classification and current evidence-based management.
Miguel Ángel Gómez-Sánchez (Madrid, Spain)
16.45 – 17.00 Scientific basis of pulmonary hypertension treatment. Is there a role for stem cell therapy?
Stephen L. Archer (Chicago, USA)
17.00 – 17.15 Pulmonary hypertension assessment in 2011. What should we wait from imaging innovation?
Irene M. Lang (Vienna, Austria)
17.15 – 17.30 Interventional and surgical modalities of treatment of pulmonary hypertension.
Julio Sandoval-Zárate (Mexico DF, Mexico)
17.30 – 17.45 Future perspective for the treatment of Pulmonary Hypertension.
Hossein A. Ghofrani (Giessen, Germany)
17.45 – 18.15 Panel discussion

FRIDAY, 10th June 2011

FRIDAY, 10th June 2011
9:00 – 9.45 BEST POSTERS PRESENTATION
9.45 – 11.50 RECENT CONTRIBUTIONS PRESENTED BY YOUNG INVESTIGATORS
9.45 – 10.00 Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial dysfunction.
Eckhard Alt (MD Anderson group. Houston, USA)
10.00 – 10.15 Differential effects of progenitor cell population on left ventricular remodelling and myocardial neovascularisation after myocardial infarction.
Dieter Dauwe (Stefan Janssens’ group. Leuven, Belgium)
10.15 – 10.30 Identification of new cardioactive paracrine factors by secretome analyses in patients un- dergoing cell therapy after myocardial infarction.
Mortimer Korf-Klingebiel (Kai C Wollert’s group. Hannover, Germany)
10.30 – 10.45 Differentiation of allogeneic mensenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair.
Xi-Ping Huang (Ren-Ke Li’s Toronto Research Institute Group. Toronto, Canada)
10.45 – 11.00 Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mensenchymal stem cells in crhonic myocardial infarction.
Atta Behfar (André Terzic’s group. Rochester, USA)
11.00 – 11.15 Heart-derived cells for post-MI ventricular dysfunction
Konstantinos Malliaras (Eduardo Marban’s group. Los Angeles, USA)
11.15-11.30 Induced pluripotent stem cell (iPSC) – derived Flk-1 progenitor cells engraft, differenriate and improve heart function in a mouse model of acute myocardial infarction.
Robert Zweigerdt (Ulrich Martin‘s group. Hannover, Germany)
11.30 – 11.50 Panel discussion
11.50 – 12.10 Coffee Break
12.10 – 14.00 NEW DEVELOPMENTS AGAINST CARDIOVASCULAR DYSFUNCTION
12.10 – 12.25 Mechanics for heart replacement and preservation
Sharon Hunt (Stanford, USA)
12.25 – 12.40 ECMO an old approach still useful
Manuel Sánchez-Luna (Madrid, Spain)
12.40 – 12.55 The revolution of trans-catheter cardiac valve replacement
Arshad Quadri (Irvine, USA)
12.55 – 13.10 The future of biologic total and partial cardiac replacement. Will xenografts play a role?
Emanuele Cozzi (Padua, Italy)
13.10 – 13.40 Surgical approaches to heart failure. Lessons from the STICH trial
Bernard Gersh (Rochester, USA)
13.40 – 14.00 Panel Discussion
14.00 – 14.45 Lunch break
14.45 – 16.30 LATE BREAKING CLINICAL TRIALS IN STEM CELL THERAPY – II
14.45 – 15.00 The APOLLO study
Patrick Serruys (Rotterdam, The Netherlands)
15.00 – 15.15 The PRECISE study
Emerson Perin (Houston, USA)
15.15 – 15.30 Effects of MAPC delivery in patients with AMI – 1 year later
Mark S. Penn (Cleveland, USA)
15.30 – 15.45 The C Cure study
Atta Behfar (Rochester, USA)
15.45 – 16.00 Helix transendocardial delivery catheter system, safety and ease of use after 100+ cases
David Snow (San Carlos, USA)
16.00 – 16.30 Panel Discussion
16.30 – 17.05 CLOSING SESSION. FIGHTING THE SPECTRUM OF LEFT VENTRICULAR FAILURE
16.30 – 16.45 Current status and future directions for cardiac cell repair therapy: The end of the beginning?
Bernard Gersh (Rochester, USA)
16.45 – 17.00 The problem of endstage left ventricular dysfunction. Is bioartificial heart the answer?
Doris Taylor (Minnesota, USA)
17.00 – 17.05 ADJOURN
Francisco Fernandez-Aviles (Madrid, Spain)
Konstantinos Malliaras
(Eduardo Marban’s group. Los Angeles, USA)